Affiliation:
1. State Research Centre for Preventive Medicine, Moscow
Abstract
The review discusses various aspects of angiotensin-converting enzyme (ACE) inhibitor therapy in patients with cardiovascular disease (CVD), including acute myocardial infarction (AMI). The focus is on the modern ACE inhibitor zofenopril, its specific pharmacological characteristics, and additional cardioprotective, anti-ischemic, and antiatherogenic effects. The existing evidence of clinical effectiveness of zofenopril and its potential for a wider use in clinical practice are also addressed.
Subject
Cardiology and Cardiovascular Medicine
Reference51 articles.
1. Mak T, Freedman AM, Dickens BF, et al. Protective effects of sulphydrylcontaining angiotensin converting enzyme inhibitors against free radical injury in endothelial cells. Biochemical. Pharmacology 1990; 40 (9): 2169–75.
2. Sun Y, Mendelsohn FA. Angiotensin converting enzyme inhibition in heart, kidney, and serum studied ex vivo after administration of zofenopril, captopril, and lisinopril. J Cardiovasc Pharmacol 1991; 18 (4): 478–86.
3. Van Gilst WH, De Graeff PA, De Leeue MJ, et al. Converting enzyme inhibitors and the role of sulphydryl group in the potentiation of exo- and endogeneous nitrovasodilatators. J Cardiovasc Pharmacol 1991; 18: 429–36.
4. De Graef PA, Van Gilst WH. The effect of bradikinin on coronary flow and its potentiation by SH-containing ACE-inhibitors. Recent Prog Kinins 1992; 38: 110–8.
5. Sacco G, Bigioni M, Evangelista S, et al. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol 2001; 414: 71–8.